Major Shakeup: CARGO Therapeutics Ends All Programs Despite $368M Cash Position - Stock Titan
2025-03-18 • Google News
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients.
2025-03-18 • Google News
2025-03-26 • Google News